# 2007

## June

**FASEB Summer Res. Conf.**  
**Ion Channel Regulation**  
June 9-14, Snowmass Village, CO  
src.faseb.org

**Gordon Res. Conf.**  
**Phosphorylation & G-Protein Mediated Signaling Networks**  
June 10-15, Biddeford, ME  
www.grc.org

**Cambridge Healthtech Inst.**  
**6th Ann. World Pharmaceutical Conf.**  
June 12-13, Philadelphia, PA  
www.worldpharmacongress.com

**Health Care Conf. Administrators LLC**  
**2nd Nat. Medicaid Congr.**  
June 13-15, Washington, DC  
www.medicaidcongress.com

**European Science Foundation Pharmacogenetics & Pharmacogenomics**  
June 15-20, Sant Feliu de Guixols, Spain  
www.esf.org/conferences/07232

**Int. Soc. for Stem Cell Res.**  
**5th Ann. Mtg.**  
June 17-20, Cairns, Queensland, Australia  
www.isscr.org

**Drug Information Assn.**  
**43rd Ann. Mtg.**  
June 17-21, Atlanta, GA  
www.diahome.org

**European Summer Schl. for Whole Animal Pharmacology**  
ESSWAP 2007 – Course on Behavioural Pharmacology  
June 17-22, Oss, The Netherlands  
www.esswap.org

**FASEB Summer Res. Conf.**  
**Signal Transduction in the Immune System**  
June 23-28, Snowmass Village, CO  
src.faseb.org

## July

**FASEB Summer Res. Conf.**  
**Protein Kinases & Protein Phosphorylation**  
July 7-12, Indian Wells, CA  
src.faseb.org

**FASEB Summer Res. Conf.**  
**ARF Family GTPases**  
July 8-13, Lucca, Toscana, Italy  
src.faseb.org

**FASEB Summer Res. Conf.**  
**The Biology of Calpains in Health & Disease**  
July 14-19, Snowmass Village, CO  
src.faseb.org

**Soc. of Toxicology of Canada & Nat. Res. Council of Canada**  
**11th Int. Congr. of Toxicology**  
July 15-19, Montreal, PQ, Canada  
www.ict2007.org

**Monash Drug Discovery**  
**Biology Initiative & ASCEPT**  
4th Int. Molecular Pharmacology of G Protein-Coupled Receptors  
July 18-19, Melbourne, Australia  

**Université Libre de Bruxelles**  
**Pancreatic Islet Res. from Fundamental to Clinical Aspects**  
July 26-29, Brussels, Belgium  
www.ulb.ac.be/medecine/hormex

## August

**13th Int. Conf. on 2nd Messengers & Phosphoproteins**  
Aug. 1-4, San Diego, CA  
www.smp-2007.com
**September**

FASEB Summer Res. Conf.
Growth Factor Reception Tyrosine Kinases in Mitogenesis, Morphogenesis, & Tumerigenesis
Aug. 11-12, Tucson, AZ
src.faseb.org

FASEB Summer Res. Conf.
Lipid Signaling Pathways in Cancer
Aug. 11-16, Indian Wells, CA
src.faseb.org

Amer. Psychological Assn.
115th Conv.
Aug. 17-20, San Francisco, CA
www.apa.org

234th Nat. Mtg.
Aug. 19-23, Boston, MA
web.mit.edu/toxms/www/news/ACS.htm

Alzheimer’s Assn.
15th Ann. Dementia Care Conf.
Aug. 26-29, Chicago, IL
www.alz.org/careconference

Dutch Soc. of Clinical Pharmacology & Biopharmacy
8th EACPT Congr. 2007
Aug. 29 – Sept. 1, Amsterdam, The Netherlands
www.eacpt2007.nl

**October**

NIH
2nd Nitrite Biology Int. Mtg.
Sept. 6-7, Bethesda, MD
www.strategicresults.com/nitrite2

Reed Medical Educat.
3rd Ann. Oncology Cong.
Sept. 7-9, San Francisco, CA
www.oncologycongress.com

Amer. Col. of Clinical Pharmacology
Sept. 9-11, San Francisco, CA
www.accp1.org

GTCbio
2nd Int. Cong. On Immune Mediated Diseases
Sept. 10-15, Moscow, Russia
www.imdconference.org

ASBMR
Sept. 16-20, Honolulu, HI
www.asbmr.org

Univ. of Wisconsin
10th Ann. Land O’Lakes Conf. of Drug Metabolism/Appl. Pharmacokinetics
Sept. 17-21, Merrimac, WI
www.pharmacy.wisc.edu/esp/drugmetabolismconference

Safety Pharmacology Soc.
Sept. 19-21, Edinburgh, Scotland
www.safetypharmacology.org

Reed Medical Educat.
3rd Ann. Chicago Supportive Oncology Conf.
Sept. 27-29, Chicago, IL
www.chicagosupportiveoncology.com

Elsevier
17th Neuropharm. Conf.–Cannabinoid Signaling in the Nervous System
Oct. 31 – Nov. 2, San Diego, CA
www.neuropharmacology-conference.elsevier.com

**November**

Amer. Soc. of Cytopathology
55th Ann. Scientific Mtg.
Nov. 2-7, Houston, TX
www.cytopathology.org

Soc. for Neuroscience
Nov. 3-7, San Diego, CA
www.sfn.org

Amer. Heart Assn.
Scientific Sessions 2007
Nov. 4-7, Orlando, FL
scientificsessions.americanheart.org

Nov. 7-10, Austin, TX
www.abrcms.org

NIH
5th Symp. on the Functional Genomics of Critical Illness & Injury
Nov. 14-15, Bethesda, MD
www.strategicresults.com/fg5

2007 Nat. Prevention & Health Promotion Summit
Nov. 27-29, Washington, DC
www.healthierus.gov

GTCPbio Inc.
3rd Ann. Modern Drug Discovery & Development Summit
Nov. 28-30, San Francisco, CA
www.gtcbio.com

Int. Soc. of Cardiovascular Pharmacotherapy
14th Int. Cong. on Cardiovascular Pharmacotherapy
Nov. 28 – Dec. 2, Antalya, Turkey
www.iscp2007.org
**December**

Amer. Soc. for Cell Biology
Dec. 1-5, Washington, DC
www.ascb.org

**2008**

**February**

Paragon Conventions
Int. Conf. on Fixed Combination in the Treatment of Hypertension & Dyslipidemia
Feb. 7-10, Budapest, Hungary
www.paragon-conventions.com/category/fixed08

**April**

Experimental Biology ’08 & ASPET’s Centennial Celebration
Apr. 5-9, San Diego, CA
www.faseb.org/meetings

Apr. 18-22, San Diego, CA
www.aacr.org

**June**

June 4-7, New Orleans, LA
www.ossdweb.org

World Conf. on Breast Cancer Foundation 5th World Conf. on Breast Cancer
June 4-8, Winnipeg, MB, Canada
www.wcbcf.ca

**July**

17th Int. Symp. on Microsomes & Drug Oxidations
July 9-16, Saratoga Springs, NY
mde2008.org

IXth World Conf. on Clinical Pharmacology & Therapeutics - CPT 2008
July 27 – Aug. 1, Quebec City, Canada
www.cpt2008.org

**August**

Amer. Psychological Assn.
116th Conv.
Aug. 14-17, Boston, MA
www.apa.org

**September**

ASBMR
Sept. 12-16, Montreal, Quebec, Canada
www.asbmr.org

**November**

Amer. Soc. of Cytopathology
56th Ann. Scientific Mtg.
Nov. 2-7, Orlando, FL
www.cytopathology.org

Nov. 5-8, Orlando, FL
www.abrcms.org

Soc. for Neuroscience
Nov. 15-19, Washington, DC
www.sfn.org

**erratum:**

Photo credit for the cover image of the February 2007 issue of *Molecular Interventions* was inadvertently omitted [Mol. Inter. 7 (2) 2007]. The credit should have read, “David M. Phillips/Photo Researchers, Inc.”
Instructions to Authors

Scope of Submitted Manuscripts

Papers published in Molecular Interventions are generally invited by the Editor after consideration of recommendations from the Editorial Advisory Board. Others who have an interest in writing for Molecular Interventions are encouraged to send proposals to the Editor. The proposal should include a detailed outline of the proposed article and a brief curriculum vitae. Articles in Molecular Interventions deal mainly with the current status of the subject under review. They are to be written clearly and concisely and should be intelligible to nonspecialists, with definitions of unfamiliar technical terms and explanations of difficult or controversial points included. At the same time, the review is to be sufficiently precise and detailed to command the attention and respect of experts in the field. Selective rather than exhaustive coverage of the literature is requested. Previous reviews of the subject and of related fields should be cited. Authors are asked to be critical of methods, results, and conclusions and to challenge accepted concepts where warranted. Conflicting points of view are to be presented objectively in good perspective. Deficiencies in the field may be pointed out and avenues for further work may be indicated. The usual length ranges between 8 and 12 printed pages, corresponding to about 24 to 36 manuscript pages. Diagrams, tables, and illustrations should be included to bring out new concepts and important relationships. The Art Director will work with the author to further develop graphics for the article. All review article manuscripts will be peer-reviewed and edited prior to publication.

Submission of Manuscripts

Submit three (3) collated hard copies of each manuscript (including illustrations) as well as an electronic version to:

Dr. Harry B. Smith, Editor
Molecular Interventions
ASPET
9650 Rockville Pike
Bethesda, MD 20814-3995

diskettes produced on PC or Mac platforms are acceptable. Microsoft Word is preferred. Authors preparing diskettes on Macintosh computers should not use the Fast Save option. Other formats and files in ASCII can be used, but are not encouraged. Authors are encouraged to supply a digital copy of their illustrations. Image files should be submitted by e-mail or on zip disks (formatted for Mac or PC) or CDs; TIFF and EPS formats are strongly preferred. Illustrations created in Adobe Illustrator, Freehand, or Corel Draw should be saved in EPS format.

A completed copy of the related Molecular Interventions Copyright Transfer form signed by the corresponding author should be included with the manuscript at the time of submission (a copy of the form is available online at www.molinterv.org). Submission of a manuscript amounts to assurance that it has received proper clearance from the author’s company or institution, that it has not been copyrighted, published, or accepted for publication elsewhere, that it is not currently being considered for publication elsewhere, and that it will not be submitted elsewhere while under consideration by Molecular Interventions. The corresponding author is responsible for obtaining permission from the copyright owner to reproduce or modify figures and tables and to reproduce text (in whole or in part) from previous publications; permissions must allow electronic reproduction as well as print. Permissions request form is available from the editorial office. The signed permissions must be submitted with the manuscript and be identified as to the relevant item in the manuscript (e.g., “permissions for Fig. 1”). In addition, a statement indicating that the material is being reprinted with permission must be included in the relevant figure legend or table footnote of the manuscript. Reprinted text must be enclosed in quotation marks, and the permission statement must be included as running text or indicated parenthetically.

Manuscripts must be in English, typewritten and double spaced throughout, including references, tables, and figure legends, using only one side of 8 1/2 by 11 inch (ca. 216 by 280 mm) paper, with at least 1 inch (23 mm) margins, and the copies must be collated. Pages should not be stapled.

Organization of the Manuscript

Manuscripts should contain the following sections in the order listed. Each section should begin on a new page and all pages should be numbered consecutively.

1. Title page. This should contain the complete title of the article, the names of all authors, and full contact information for corresponding author (address, phone, fax, e-mail). A running title and at least five keywords should also be given.

2. Abstract. The abstract should be approximately 100 words, and should provide the context in which the topic of the article should be appreciated. The abstract should be intelligible to the general reader without reference to text. Reference citations are not permitted in abstracts, and nonstandard abbreviations should not be included.

3. Body of manuscript. It is highly recommended that the body be divided into conceptual sections, the first of which should be labeled INTRODUCTION and the last of which should be labeled CONCLUSIONS. Section headings should be given in all capital letters, subsection headings in standard title format, and sub-subsection headings in italics.

4. Acknowledgments. The Acknowledgments section is placed at the end of the text.

5. References. References are cited in the text by number. In the reference list, the references should be arranged in the order in which they are first cited in the text. The names of all authors should be given in the reference list. Abbreviations for journals should conform to the BIOSIS List of Serials (BioSciences Information Services of Biological Abstracts, Philadelphia, PA 19103) References to personal communications, unpublished observations, and papers submitted for publication are given in parentheses at the appropriate location in the text, not in the list of references. Only papers that have been officially accepted for publication may be cited as ‘in press’ in the reference list. The authors are responsible for the accuracy of the references. The format for journal article, chapter, and book references is as follows:


6. Tables. Each table must be on a separate page. The tables are numbered consecutively with Arabic numerals, and designed to fit the column or page size of the journal. A brief descriptive title is provided at the top of each table. General statements about the table follow the title in paragraph form. Footnotes to tables are referenced by italicized, lower case, superscript letters (a, b, c, etc.) and defined beneath the table.

7. Legends for figures. Figures are numbered consecutively with Arabic numerals, with each one displayed on a separate page. Legends must provide sufficient explanation for the reader to understand the figure independent of the text.

8. Figures. Submit illustrations as glossy photographs, original India-ink drawings, or high-resolution laser printer output. Lettering on figures should be large enough to be legible after reduction to single-column width of 21 picas (about 3.5 inches or 9 cm). Letter sizes after reduction should be 6–8 points. Do not use varying letter typesizes within a single figure; use the same size or similar sizes throughout the drawing. All panels of a multipart figure should be provided on the same page. Although each of the manuscript copies should contain a complete set of figures, only the originals need be of the quality suitable for reproduction. In the case of halftones, three sets of photographs are required. If symbols are not explained on the face of the figure, only standard print characters may be used. The back of each figure should bear its number, the name of the first author, and the word TOP at the appropriate edge. Include figure titles in the legend and not on the figure itself. Photomicrographs and electron micrographs must be labeled with a magnification calibration in micrometers or Angstrom units. A statement concerning the magnification must appear in the figure legend.

9. Author Photographs. Supply a color glossy photograph of each author. Head size (top of head to bottom of chin) should be no smaller than 1.5 inches; also allow generous room on all sides for cropping. Write full name on back of photos, identify multiple authors as necessary. Digital images of approximately 4MB are acceptable.

10. Additional images. All authors are encouraged to submit images to be considered for use on the cover of Molecular Interventions. Cover images should be submitted as glossy (8x10) prints, transparencies or negatives, or as high-resolution digital files. Cover submissions should be accompanied by a 100-word description of the image. In addition, the title of each review article will be highlighted by an image selected by the editorial office; authors are encouraged to supply images with an appropriate caption for title treatment. Consult a recent issue of Molecular Interventions for examples.

Abbreviations, Drug Names, Gene Names, etc.

All abbreviations and technical nomenclature should be explained in parentheses upon their first use in the text. Do not abbreviate terms (other than standard abbreviations) that are used less than three times in the text. Generic drug names are used in text, tables, and figures. Trade names may be given in parentheses following the first text reference, but should not appear in titles, figures, or tables. Whereas trade names are capitalized, generic or chemical names are not.